| Condition | Initial diagnosis | Follow for med adjustment | How often | Watch out |
|---|---|---|---|---|
| Thyrotoxicosis | ||||
| Graves disease on MMI/PTU | TSH, FT4, total T3, TRAb (or TSI). CBC w/diff + LFTs before ATD. | FT4 + total T3. Add TSH once FT4/T3 normal. | 4 to 6 wk until euthyroid, then q2 to 3 mo on maintenance. TRAb at 12 to 18 mo before trial off. | TSH lags for months; don't chase it early. T3 can stay high while FT4 normalizes ("T3 predominant" Graves). |
| Graves after RAI | As above (already diagnosed) | FT4 + total T3, then TSH once on levothyroxine | 1 to 2 mo after RAI, then q4 to 6 wk for ~6 mo | Most become hypothyroid (the goal). Low TSH early after RAI does not mean still hyper. |
| After total thyroidectomy | As above | TSH (on levothyroxine). Calcium ± PTH post op. | TSH at 6 to 8 wk after starting levothyroxine | Starting dose ~1.6 μg/kg/day. Hypocalcemia from hypoparathyroidism in the first days. |
| Toxic adenoma / toxic MNG | TSH, FT4, total T3, RAIU / scintigraphy (hot nodule or patchy uptake), thyroid US | FT4 + total T3 | 4 to 6 wk on MMI; after RAI or surgery, 1 to 2 mo then q4 to 6 wk | Often T3 toxicosis (normal FT4, high T3), so always order T3. Does not remit on ATD; definitive therapy is the plan. |
| Thyroiditis (painless, postpartum, subacute) | TSH, FT4, total T3 (T3:T4 <20), low RAIU, TRAb negative. Subacute: ESR/CRP high, tender gland. | TSH + FT4 | q4 to 8 wk through the hyper phase, the hypo phase, and recovery (~6 mo) | No ATDs (nothing to block; it's leakage). β-blocker for symptoms; NSAID or prednisone for subacute pain. Watch for permanent hypothyroidism. |
| Amiodarone induced (AIT) | TSH, FT4, total T3, TRAb, thyroid US with Doppler (flow high in type 1, absent in type 2) | FT4 + total T3 | q4 to 6 wk | Type 1: MMI. Type 2: prednisone. Mixed or unclear: both. RAIU usually low from the iodine load, so less helpful. |
| ICI thyroiditis | TSH + FT4 (baseline before ICI) | TSH + FT4 | Every cycle or q4 to 6 wk on therapy | Destructive: no ATDs. Often turns into permanent hypothyroidism within 1 to 3 months. |
| Subclinical hyperthyroidism | Low TSH, normal FT4 and T3 | TSH, FT4, total T3 | Repeat in 6 to 12 wk to confirm (many resolve) | Rule out steroids, dopamine, recovery from illness, first trimester. Treat if TSH <0.1 and age ≥65, AF, osteoporosis. |
| Hypothyroidism | ||||
| Primary hypothyroidism on levothyroxine | TSH high + FT4 (low = overt, normal = subclinical). TPO Ab if cause unclear. | TSH | 6 to 8 wk after any dose change; q6 to 12 mo once stable | Draw timing vs. the morning dose matters for FT4 (falsely high right after a dose), not for TSH. Absorption drops with calcium, iron, PPIs, food. |
| Central (secondary) hypothyroidism | Low FT4 with low or inappropriately normal TSH. Check other pituitary axes (AM cortisol first). | FT4 (aim upper half of normal) | 6 to 8 wk after dose change | TSH is useless here. Replace cortisol before thyroid hormone if adrenal insufficiency. |
| Subclinical hypothyroidism | High TSH, normal FT4. TPO Ab. | TSH + FT4 | Repeat in 6 to 12 wk to confirm, then q6 to 12 mo | Rule out recovery from illness, macro TSH, assay interference. Treat usually if TSH >10 or pregnancy. |
| Special situations | ||||
| Pregnancy, hyperthyroid | Trimester specific TSH, FT4 (or total T4), TRAb | FT4 (or total T4), aim at or just above the upper limit of normal | q4 wk | PTU 1st trimester, usually MMI after ~16 wk (individualize).[25] Lowest ATD dose; overtreating causes fetal hypothyroidism. TRAb at 18 to 22 wk. |
| Pregnancy, on levothyroxine | TSH (trimester specific range) | TSH | q4 wk until ~20 wk, then once at ~30 wk | Increase dose ~25 to 30% as soon as pregnancy confirmed (e.g., 2 extra doses per week). |
| Thyroid storm (ICU) | TSH, FT4, total T3, TRAb. BWPS score. CBC, LFTs, cortisol. | FT4 (FT3 as backup). Not total T3, not TSH. | Daily to every 2 to 3 days while titrating | Total T3 reads falsely low in critical illness (low binding proteins, nonthyroidal illness). Steroid taper is clinical, not FT4 driven. See Part 3, Lab Monitoring in the ICU. |
| Critically ill, no known thyroid disease | Usually don't check unless thyroid disease is really suspected | n/a | Recheck 4 to 6 wk after recovery | Nonthyroidal illness: low T3, then low TSH and FT4; TSH can overshoot high during recovery. Steroids and dopamine suppress TSH. |
| Situation | Follow | How often | Dose adjustment | Recheck sooner if |
|---|---|---|---|---|
| Hyperthyroid on antithyroid drug | ||||
| MMI, titration phase | FT4 + total T3 (TSH not yet useful) | About every 4 to 6 wk | When FT4 normalizes, usually cut the dose by approximately 30 to 50% | Symptoms return, adherence questions, or any fever / sore throat (STAT CBC) |
| MMI, stable maintenance | TSH + FT4 (± total T3) | About every 2 to 3 mo; if on long term low dose MMI beyond ~18 mo, approximately every 4 to 6 mo | Usually 5 to 10 mg/day; adjust in small steps (approximately 2.5 to 5 mg) | New symptoms, pregnancy planned, new rash, jaundice, dark urine |
| Deciding to stop MMI | TRAb + TSH + FT4 | At about 12 to 18 mo of therapy | TRAb normal: trial off is reasonable. Still high: probably continue, or plan RAI / surgery | n/a |
| After stopping MMI (remission) | TSH + FT4 + total T3 | About every 1 to 3 mo for the first 6 mo, then every 3 to 6 mo for the first year, then at least yearly | Relapse: restart MMI or move to definitive therapy | Most relapses probably happen in the first year; recheck with any symptoms or pregnancy |
| After definitive therapy | ||||
| After RAI | FT4 + total T3 first, then TSH once on levothyroxine | At 1 to 2 mo, then about every 4 to 6 wk until stable (approximately 6 mo); then yearly for life | Start levothyroxine when FT4 falls below normal; then titrate by TSH | Fatigue, weight gain, cold intolerance (likely hypothyroid) |
| After total thyroidectomy | TSH | 6 to 8 wk after starting levothyroxine, then every 6 to 12 mo once stable | Start approximately 1.6 μg/kg/day; adjust by 12.5 to 25 μg | Tingling or cramps early post op (check calcium) |
| Hypothyroid on levothyroxine | ||||
| Primary hypothyroidism, titration | TSH | 6 to 8 wk after every dose change | Adjust by approximately 12.5 to 25 μg; smaller steps if elderly or cardiac | Palpitations or chest pain (possible overreplacement) |
| Primary hypothyroidism, stable | TSH | About every 12 mo (some check every 6 mo) | Only if TSH out of range on repeat | Pregnancy, weight change of approximately 10% or more, new estrogen, PPI, iron, calcium, or bile acid binder, malabsorption, age-related decline |
| Central hypothyroidism | FT4 (TSH useless) | 6 to 8 wk after a change, then every 6 to 12 mo | Aim for the upper half of normal FT4 | Pituitary changes, new glucocorticoid or growth hormone therapy |
| Watching without treatment | ||||
| Subclinical hyperthyroidism (not treated) | TSH, FT4, total T3 | About every 6 to 12 mo | Treat if it progresses or TSH stays below approximately 0.1 with risk factors | New AF, bone loss, symptoms |
| Subclinical hypothyroidism (not treated) | TSH (± FT4) | About every 6 to 12 mo; probably yearly if TPO Ab positive | Treat if TSH rises above approximately 10, symptoms, or pregnancy | Pregnancy planned or confirmed |
| After thyroiditis recovers (painless, postpartum, subacute) | TSH | About yearly | Levothyroxine if permanent hypothyroidism develops | Future pregnancy (postpartum thyroiditis often recurs) |
| Drugs that affect the thyroid | ||||
| Amiodarone | TSH (± FT4, total T3) | About every 3 to 6 mo on therapy; continue for approximately 6 to 12 mo after stopping | Per type of dysfunction | New palpitations, AF recurrence, weight loss |
| Lithium | TSH | Baseline, then about every 6 to 12 mo | Levothyroxine if hypothyroid (lithium can usually continue) | Goiter, fatigue, weight gain |
| Immune checkpoint inhibitor | TSH + FT4 | Every cycle or about every 4 to 6 wk on therapy, then periodically after | Levothyroxine for hypothyroid phase; no ATDs | Fatigue, palpitations, headache (consider hypophysitis: check cortisol) |
| TSH | FT4 | T3 | Think | Next step |
|---|---|---|---|---|
| ↓ | ↑ | ↑ | Overt hyperthyroidism | TRAb; RAIU only if TRAb negative |
| ↓ | Normal | ↑ | T3 toxicosis (early Graves, toxic nodule) | TRAb, RAIU / scintigraphy |
| ↓ | Normal | Normal | Subclinical hyper, steroids, dopamine, recovering illness, 1st trimester | Repeat in 6 to 12 wk |
| ↓ or normal | ↓ | ↓ | Central hypothyroidism or nonthyroidal illness | AM cortisol, pituitary panel / MRI if not ICU |
| ↑ | ↓ | ↓ or normal | Primary hypothyroidism | Start levothyroxine; TPO Ab if cause unclear |
| ↑ | Normal | Normal | Subclinical hypo, recovery from illness, macro TSH | Repeat with TPO Ab in 6 to 12 wk |
| Normal or ↑ | ↑ | ↑ or normal | Doesn't fit: biotin, heparin, heterophilic antibody, amiodarone, levothyroxine taken right before the draw, TSH-oma, thyroid hormone resistance | Ask about supplements and heparin; rerun on a different platform; then pituitary MRI |
| Cause | TRAb | T3:T4 | RAIU | Thyroglobulin | Clue | ATD helps? |
|---|---|---|---|---|---|---|
| Graves disease | + | >20 | High, diffuse | High | Eye disease, diffuse goiter, bruit | Yes |
| Toxic adenoma / MNG | − | >20 | Hot nodule / patchy | High | Palpable nodule(s), older patient | Yes (bridge to RAI or surgery) |
| Painless / postpartum thyroiditis | − | <20 | Low | High | Within 12 mo postpartum, TPO Ab + | No |
| Subacute (de Quervain) | − | <20 | Low | High | Painful tender gland after viral illness, ESR/CRP high | No |
| Exogenous thyroid hormone | − | Depends on what was taken | Low | Low | No goiter; the only cause with low thyroglobulin | No (stop the source) |
| AIT type 1 | − | Variable | Low to normal | High | Pre-existing goiter; Doppler flow high | Yes |
| AIT type 2 | − | Variable | Low | High | Normal gland; Doppler flow absent | No (prednisone) |
| ICI thyroiditis | − | <20 | Low | High | On anti PD-1 / CTLA-4 | No |
T3:T4 ratio = total T3 (ng/dL) ÷ total T4 (μg/dL).
| Antibody | Target / meaning | Clinical use |
|---|---|---|
| TRAb | Antibody against the TSH receptor — encompasses stimulating, blocking, and neutral forms | Pathognomonic for Graves disease — sensitivity 97.7%, specificity 99.5%. If positive, no imaging needed. Single most useful test in suspected GD. |
| TSI | Functional subset of TRAb that specifically stimulates the TSH receptor (bioassay) | Correlates with Graves ophthalmopathy (GO) severity. Predicts recurrence risk after ATD (antithyroid drug) course. Useful when TRAb is borderline or when monitoring GO activity. |
| TPO Ab | Antibody against thyroid peroxidase enzyme | Marker of autoimmune thyroid disease broadly — present in ~75% of GD, ~95% of Hashimoto, and ~10% of the general population. Confirms autoimmunity but not specific to GD. |
| TgAb | Antibody against thyroglobulin | Another autoimmune marker; less diagnostically useful. Critical post-thyroidectomy for cancer surveillance — interferes with Tg (thyroglobulin) assays and must be measured alongside Tg. |
When to order which:
Thyroid hormone levels in thyroid storm are indistinguishable from those in compensated thyrotoxicosis.[1][2] The Burch-Wartofsky Point Scale (BWPS) — the standard scoring system for thyroid storm — is based entirely on clinical parameters with zero laboratory criteria.[3]
(≥45 = thyroid storm; 25–44 = impending storm; <25 unlikely)[3]
| Category | Gradations |
|---|---|
| Temperature | °F (graded bands from 99 to ≥104) |
| CNS effects | absent → mild agitation → moderate (delirium, psychosis, extreme lethargy) → severe (seizure, coma) |
| GI-hepatic dysfunction | absent → moderate (diarrhea, N/V, abdominal pain) → severe (unexplained jaundice) |
| Heart rate | bpm (graded bands from 99 to ≥140) |
| CHF | absent → mild (pedal edema) → moderate (bibasilar rales) → severe (pulmonary edema) |
| Atrial fibrillation | present or absent |
| Precipitating event | present or absent |
Block and Brake are used in every case. Boost and Bind are add-ons for severe/refractory disease. Break is definitive therapy.[1][2]
Symptom control. Propranolol at doses ≥160 mg/day may additionally inhibit peripheral T4-to-T3 conversion by approximately 20–30%, though this is probably of limited clinical significance at usual doses; its main benefit is nonselective symptom control.[2][3][8]
| Agent | Dose | Frequency | Key features |
|---|---|---|---|
| Propranolol (preferred) | 10–40 mg start; up to 320 mg/day | TID–QID | Nonselective; may modestly block T4→T3 at high doses (probably minor clinically) |
| Propranolol LA | 60–160 mg | Once daily | Better adherence; same drug |
| Atenolol | 25–100 mg | QD–BID | β1-selective; avoid in pregnancy |
| Metoprolol | 25–50 mg | BID–TID | β1-selective; widely available |
| Nadolol | 40–160 mg | Once daily | Nonselective; may block T4→T3 |
When β-blockers contraindicated (asthma, decompensated CHF, bradyarrhythmia, Raynaud) → non-DHP CCB (non-dihydropyridine calcium channel blocker):[3][5]
Methimazole (MMI) is first-line over propylthiouracil (PTU) for three reasons:[2][6]
| FT4 level | MMI starting dose | This patient? |
|---|---|---|
| 1.0–1.5× ULN | 5–10 mg/day | — |
| 1.5–2.0× ULN | 10–20 mg/day | — |
| 2.0–3.0× ULN | 30–40 mg/day | ✓ FT4 3.63 = 2.1× ULN |
| >3.0× ULN (severe) | 40–60 mg/day | consider inpatient |
Before starting any ATD: baseline CBC w/diff and LFTs — not to preclude treatment, but as a reference for later agranulocytosis (0.2–0.5% risk, highest in first 90 days, peak approximately 1–2 months) or hepatotoxicity questions.[2][6]
The standard approach is the titration method — preferred over "block-and-replace" because the latter requires higher ATD doses with more side effects and no proven benefit.[1][4]
A survey found that 61% of patients on ATDs were unfamiliar with the symptoms of agranulocytosis.[2] Communicate clearly — ideally both verbally and in writing.
STAT CBC with differential and LFTs.[1][2]
| Finding | Action |
|---|---|
| ANC <0.5 × 10⁹/L = agranulocytosis | Stop MMI permanently; admit; broad-spectrum antibiotics; G-CSF (granulocyte colony-stimulating factor) |
| ANC <1.0 but >0.5 | Concerning — hold drug, recheck in 24–48 hours |
| LFTs: hepatocellular injury (AST/ALT >3× ULN or rising bilirubin) | Stop MMI; do not rechallenge |
Duration: treat 12–18 months, then check TRAb — if normalized, trial off. Remission rate ~40–50%. Long-term low-dose MMI is safe if remission not achieved.[2]
For patients needing faster hormone reduction: cholestyramine 4 g PO BID–QID (even 1–2 g BID effective) binds T4/T3 in the gut, interrupting enterohepatic recirculation. At 4 weeks, significant additional FT4 reduction (mean diff −1.0 ng/dL) vs standard therapy alone.[7]
All steps initiated simultaneously, with one critical timing exception noted.[3][4]
Dexamethasone has the best-documented and most potent inhibition of peripheral T4-to-T3 conversion among glucocorticoids. Dexamethasone 8 mg/day reduces serum T3 by 37–50% in Graves disease, with T3 beginning to fall at 24 hours and remaining suppressed for ≥5 days.[22] This effect is explicitly "exploited therapeutically" in severe thyrotoxicosis.[8]
| Steroid | T4→T3 blockade | Dose studied | T3 reduction |
|---|---|---|---|
| Dexamethasone | Strong, well-documented | 2 mg q6h (8 mg/day) | 30–50% |
| Hydrocortisone | Probable, less well-characterized — ATA says it "may" block T4→T3 | 300 mg load → 100 mg q8h | Not well quantified |
| Prednisone | Minimal at standard doses | 20 mg/day | No significant change |
FDA levothyroxine labeling cites glucocorticoids ≥dexamethasone 4 mg/day as the threshold for the ~30% T3 reduction class effect. Methylprednisolone and betamethasone aren't specifically studied for this indication, but high-potency synthetic glucocorticoids at supraphysiologic doses are expected to share the effect — higher potency and higher dose correlate with greater inhibition of peripheral deiodination.[21]
There is no published, standardized dexamethasone taper protocol for thyroid storm in any guideline — ATA and expert reviews simply say "taper and discontinue once clinical improvement occurs."[3][21] A reasonable decision-tree:
| Timepoint | State | Action |
|---|---|---|
| Day 0 | Initial storm management | Dexamethasone 2 mg IV q6h + PTU + propranolol + SSKI (≥1 hr after PTU) |
| Day 2–3 | Improving (↓HR, ↓temp, AMS clearing) | Begin taper: 2 mg q12h × 1 d → 2 mg daily × 1 d → stop |
| Day 2–3 | NOT improving | Continue full dose; consider TPE or emergency thyroidectomy |
Typical total course ≤ 5 days. Taper is based on clinical improvement, not a specific FT4 or TSH cutoff. Dexamethasone serves two time-limited purposes (T4→T3 blockade + coverage for relative adrenal insufficiency); prolonged courses don't add benefit and carry the usual steroid risks.
Preoperative preparation for emergency thyroidectomy: dexamethasone should be tapered within the first 72 hours after surgery.[21] Panzer et al. used a lower-dose regimen (dexamethasone 1 mg BID) in combination with iopanoic acid and thionamides for rapid preoperative preparation, continuing until patients were clinically euthyroid — typically days to a couple of weeks.[24]
Supportive: cooling blankets (not aspirin), volume resuscitation, antibiotics if infection is precipitant, nutritional support, ICU monitoring.[3][4]
| Marker | Use in the ICU |
|---|---|
| Free T4 | Primary trending marker. Most reliable in the ICU; less affected by binding-protein changes than total T3. |
| Free T3 | Reasonable secondary marker despite assay imprecision (see below). |
| Total T3 | Do NOT rely on this in the ICU. Confounded by low binding proteins (TBG, albumin) and NTIS (non-thyroidal illness syndrome). Can read paradoxically low despite active thyrotoxicosis. |
| TSH | Useless acutely — stays suppressed for weeks to months after thyrotoxicosis resolves. |
Both RAI and total thyroidectomy are equally effective at curing Graves disease (definitive cure >90%). The choice is driven by patient anatomy, comorbidities, GO status, pregnancy plans, and patient preference. Both render the patient hypothyroid (intentional in GD) and both require lifelong levothyroxine.
| Factor | Favors RAI | Favors thyroidectomy |
|---|---|---|
| Goiter size | Small to moderate (<80 g) | Large (≥80 g) — RAI less effective; compressive symptoms (dyspnea, dysphagia, stridor) |
| Nodules | None suspicious | Suspicious nodule on US/FNA requiring histology |
| Graves ophthalmopathy | None or mild/inactive | Moderate-severe active GO, especially in smokers (RAI can worsen GO) |
| TRAb level | Low to moderate | Very high TRAb — predicts RAI failure |
| Pregnancy plans | Not planning within 6–12 months | Pregnancy planned <6–12 months; pregnant in 2nd-3rd trimester |
| Coexisting hyperparathyroidism | — | Combined parathyroidectomy + thyroidectomy in one operation |
| Surgical / anesthesia risk | High cardiopulmonary risk | Acceptable surgical risk |
| Access to surgeon | No experienced thyroid surgeon available | High-volume thyroid surgeon available — complication rates depend heavily on surgeon volume |
| Speed of resolution | OK with weeks-to-months | Need rapid, immediate control |
| Patient preference | Avoid surgery / scar | Avoid radiation exposure; want definitive same-day control |
| Cost / logistics | Lower cost; outpatient single visit | Higher cost; OR + inpatient stay |
| Approach | Risks |
|---|---|
| RAI | Permanent hypothyroidism (expected, requires lifelong levothyroxine); worsening of active GO (use prednisone prophylaxis if active GO, especially in smokers); transient radiation thyroiditis with worsening thyrotoxicosis (1–3%); rare salivary gland damage; pregnancy/breastfeeding contraindicated 6–12 months |
| Total thyroidectomy | Transient hypoparathyroidism (~10–20%); permanent hypoparathyroidism (1–4%); RLN injury (1–4%); permanent hypothyroidism (100%); general surgical/anesthesia risks; complication rates strongly dependent on surgeon volume |
In the ICU/storm setting, the only definitive option is emergency total thyroidectomy, reserved for:
Bridge to OR: β-blocker + iodine (SSKI) + dexamethasone + cholestyramine ± TPE. The Panzer protocol (iopanoic acid + dexamethasone + thionamide) is used at experienced centers for rapid preoperative preparation.[24] Emergency thyroidectomy in the storm setting historically carried 10–30% mortality but is substantially lower at high-volume centers with multidisciplinary preparation.[4]
Definitive therapy after recovery: plan RAI or thyroidectomy as an outpatient once the patient is euthyroid on ATDs and the iodine load has washed out — typically 2–6 weeks after stopping SSKI, since residual iodine reduces RAI uptake and effectiveness.
| Drug | Common | Serious / rare | Monitoring |
|---|---|---|---|
| MMI | Rash/urticaria (6%), arthralgias (1–5%), GI upset, taste/smell changes | Agranulocytosis (0.2–0.5%, highest first 90 days, peak ~1–2 mo); cholestatic hepatitis (0.4%); pancreatitis; embryopathy (1st trimester) | Baseline CBC + LFTs; symptom-based (fever/sore throat → STAT CBC) |
| PTU | Rash/urticaria (3%), arthralgias, GI upset | ⚠️ FDA boxed warning: fulminant hepatic necrosis (2.7%); agranulocytosis (0.2–0.5%); ANCA (anti-neutrophil cytoplasmic antibody)-positive vasculitis (up to 3%, increases with duration) | Baseline CBC + LFTs; symptom-based |
| Propranolol | Fatigue, cold extremities, bradycardia, dizziness, GI upset | Bronchospasm, severe bradycardia, hypotension, masking of hypoglycemia, depression | HR/BP; glucose in diabetics |
| Esmolol (IV) | Hypotension (dose-dependent), injection site reactions | Severe bradycardia, bronchospasm | Continuous HR/BP (ICU) |
| Diltiazem | Bradycardia, hypotension, peripheral edema, constipation, dizziness | AV block, severe hypotension (esp. with β-blocker combo), worsening CHF | HR, BP, ECG |
| Verapamil | Same as diltiazem + more constipation | Stronger negative inotropy — avoid in HFrEF; AV block | HR, BP, ECG, LV function |
| SSKI / KI (potassium iodide) | Metallic taste, nausea, sialadenitis, acneiform rash | Iodine hypersensitivity (rare); escape from Wolff-Chaikoff after 1–2 wk; ⚠️ give ≥1 hr after ATD | TFTs; limit to 7–14 days in storm |
| Hydrocortisone | Hyperglycemia, fluid retention, insomnia, GI upset | Adrenal suppression (prolonged), infection risk, GI bleed, psychosis (high dose) | Glucose; taper when storm resolves |
| Dexamethasone | Hyperglycemia, insomnia, mood changes | Same as HCT (hydrocortisone) but no mineralocorticoid effect (less fluid); adrenal suppression | Glucose |
| Cholestyramine | Constipation (most common), bloating, abdominal discomfort, nausea | Impaired absorption of other drugs (separate by 1 hr before / 4 hr after); fat-soluble vitamin malabsorption (A, D, E, K) with prolonged use | Timing of other meds; stool frequency |
| RAI | Transient neck pain/swelling, radiation thyroiditis (1–3%), transient worsening of thyrotoxicosis | Permanent hypothyroidism (expected in GD); worsening of GO — steroid prophylaxis if active GO; rare salivary damage | TFTs q4–6 wk post-RAI; lifelong levothyroxine |
Critical section — these substances cause spurious TFT results in euthyroid patients, leading to misdiagnosis and inappropriate treatment. Over 50% of documented thyroid assay interferences have led to misdiagnosis and/or inappropriate management.[9]
| Substance | TSH | FT4 | T3 | Condition mimicked | Mechanism / what to do |
|---|---|---|---|---|---|
| Biotin (vit B7) | ↓ falsely low | ↑ falsely high | ↑ falsely high | Primary hyperthyroidism (can cause false-positive TRAb) | Competes with biotinylated reagents in streptavidin-biotin immunoassays. Stop ≥2–7 days before retest; interference possible at doses as low as 10 mg/day |
| Heparin / enoxaparin | Normal | ↑ falsely high | ↑ falsely high | TSH-oma, thyroid hormone resistance | Generates FFAs (free fatty acids) in vitro that displace T4 from binding proteins. Draw blood before heparin dose; analyze immediately |
| Heterophilic antibodies (e.g., HAMA, human anti-mouse antibodies) | ↑ or ↓ | Variable | Variable | Various | Cross-react with assay antibodies. Method comparison on different platform; heterophilic blocking reagents |
| Macro-TSH | ↑ falsely high | Normal | Normal | Subclinical hypothyroidism (~1% of cases) | TSH bound to immunoglobulins; cleared slowly. PEG (polyethylene glycol) precipitation; gel filtration |
| Drug | Thyroid effect | Mechanism | Monitoring |
|---|---|---|---|
| Amiodarone | Hypothyroidism (13–17%) or thyrotoxicosis (AIT (amiodarone-induced thyrotoxicosis), 9%); 5-yr cumulative ~40% | AIT type 1: iodine excess → ↑ synthesis (pre-existing goiter); AIT type 2: destructive thyroiditis; hypothyroidism: direct toxicity + Wolff-Chaikoff | TSH q3–6 mo on therapy, then q6 mo; continue 6–12 mo after stopping (t½ ~100 d) |
| Lithium | Hypothyroidism (5–15%); goiter; rarely hyperthyroidism | Inhibits iodine uptake, hormone synthesis, and release; ↑ thyroid autoimmunity | TSH baseline, q6–12 mo |
| ICIs (immune checkpoint inhibitors) (anti-PD-1 (programmed cell death protein-1), anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein-4)) | Thyrotoxicosis (transient, destructive) → often evolves to hypothyroidism (50–90%); most common endocrine irAE (immune-related adverse event) | Cytotoxic T-cell-mediated thyroid destruction; ATDs NOT indicated (destructive, not synthetic) | TSH + FT4 q4–6 wk during therapy |
| TKIs (tyrosine kinase inhibitors) (sunitinib, sorafenib) | Hypothyroidism (up to 27%) | Destructive thyroiditis; impaired iodine uptake; capillary regression | TSH q4–8 wk |
| Interferon-α | Hypo- or hyperthyroidism; autoimmune thyroiditis | Autoimmune | TSH q3 mo during therapy |
| Alemtuzumab | Graves disease in up to 30–40% | Immune reconstitution → autoimmune GD | TSH q3 mo for 4 yr after last dose |
| Drug / class | Effect on TFTs | Mechanism | Clinical significance |
|---|---|---|---|
| Oral estrogen (OCP (oral contraceptive pill), HRT (hormone replacement therapy)) | ↑ Total T4/T3 (FT4 usually normal) | ↑ TBG production (hepatic first-pass) | Patients on levothyroxine may need dose increase; transdermal estrogen has minimal effect |
| Androgens, glucocorticoids, niacin | ↓ Total T4/T3 (FT4 usually normal) | ↓ TBG production | Rarely clinically significant; glucocorticoids also suppress TSH centrally |
| Phenytoin, carbamazepine | ↓ FT4 (assay artifact); normal TSH | Displace T4 from binding proteins + enhance T4 metabolism via CYP (cytochrome P450) induction | Artifactually low FT4 mimics central hypothyroidism — patient is euthyroid; levothyroxine dose may need increase |
| Salsalate | ↓ FT4; normal TSH | Displaces T4 from binding proteins | Same artifact as phenytoin — patient is euthyroid |
| Cholestyramine, colestipol | ↓ T4/T3 levels | Binds thyroid hormone in gut; impairs levothyroxine absorption | Separate levothyroxine dosing by ≥4 hours |
| Metformin | ↓ TSH in hypothyroid patients | Unclear; may enhance TSH suppression | May cause apparent "improvement" in subclinical hypothyroidism — not a true thyroid effect |
| Glucocorticoids (high dose) | ↓ TSH; ↓ T3 | Central TSH suppression + inhibit T4→T3 conversion | Can mimic central hypothyroidism or mask thyrotoxicosis; dose-dependent and reversible |
Confirmed Graves disease — TRAb 11.60 and TSI 7.83 are both markedly elevated, confirming the diagnosis without need for imaging.[2]
Thyrotoxic hepatitis — AST 229 → 21 and ALT 184 → 33 normalization without liver-directed therapy is classic. The hepatocellular pattern (AST/ALT predominant) is the typical thyrotoxic pattern, distinct from the cholestatic pattern of MMI-induced hepatotoxicity. This means the 5/11 labs (post-resolution) — not the 4/20 labs — serve as the true pre-ATD baseline.
Thyroid- and specialty-specific terms only. Universal medical abbreviations (TSH, FT4, BID, IV, ICU, HR, BP, ECG, AST, ALT, CBC, etc.) are not listed.
| Abbreviation | Expansion | Abbreviation | Expansion |
|---|---|---|---|
| AIT | Amiodarone-induced thyrotoxicosis | NTIS | Non-thyroidal illness syndrome |
| ANCA | Anti-neutrophil cytoplasmic antibody | OCP | Oral contraceptive pill |
| ATD | Antithyroid drug | PD-1 | Programmed cell death protein-1 |
| BWPS | Burch-Wartofsky Point Scale | PEG | Polyethylene glycol |
| CCB | Calcium channel blocker | PTU | Propylthiouracil |
| CTLA-4 | Cytotoxic T-lymphocyte-associated protein-4 | RAI | Radioactive iodine |
| CYP | Cytochrome P450 | RAIU | Radioactive iodine uptake |
| DHP | Dihydropyridine | RDI | Recommended daily intake |
| FFA | Free fatty acid | RLN | Recurrent laryngeal nerve |
| G-CSF | Granulocyte colony-stimulating factor | rT3 | Reverse triiodothyronine |
| GD | Graves disease | SSKI | Saturated solution of potassium iodide |
| GO | Graves ophthalmopathy | TBG | Thyroxine-binding globulin |
| HAMA | Human anti-mouse antibodies | TFT | Thyroid function test |
| HCT | Hydrocortisone | Tg | Thyroglobulin |
| HFrEF | Heart failure with reduced ejection fraction | TgAb | Thyroglobulin antibody |
| HPA | Hypothalamic-pituitary-adrenal (axis) | TKI | Tyrosine kinase inhibitor |
| HRT | Hormone replacement therapy | TPE | Therapeutic plasma exchange |
| ICI | Immune checkpoint inhibitor | TPO Ab | Thyroid peroxidase antibody |
| irAE | Immune-related adverse event | TRAb | TSH receptor antibody |
| KI | Potassium iodide | TSH-oma | TSH-secreting pituitary adenoma |
| LA | Long-acting | TSI | Thyroid-stimulating immunoglobulin |
| MMI | Methimazole | ULN | Upper limit of normal |
| MNG | Multinodular goiter | WPW | Wolff-Parkinson-White |
| MS | Multiple sclerosis | t½ | Half-life |